Novo Integrated Sciences Provides Update on Pending Transactions

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) has recently provided an update on several pending transactions that are expected to significantly impact the company’s growth and development. These transactions include the Blacksheep Trust One Billion Dollar Master Collateral Transfer Agreement, a funding commitment from Sheikh Khaled bin Mohammad bin Fahad Al Thanayan, and a promissory note with RC Consulting LLC.

The Collateral Transfer Facility, which is a common financing tool in European and Asian marketplaces, will involve the transfer of a gold-backed guarantee as collateral. An independent PCAOB auditor will conduct validation and authentication of the collateral, which will then be reflected on Novo’s balance sheet. Once the collateral transfer is complete, the company plans to leverage it to obtain a substantial line of credit, securing it solely with the collateral and leaving the rest of the company’s assets unencumbered.

As part of the Collateral Transfer Facility, Novo will compensate Blacksheep Trust, a New York-based private express trust, with a prescribed fee of 15% of the monetization amount. Additionally, Blacksheep Trust will be entitled to an annual distribution of 10% of net profits resulting from the direct investment of funds derived from monetization.

The funding commitment from Sheikh Khaled bin Mohammad bin Fahad Al Thanayan, through Gulf International Minerals and Energy Group (GIMEG), amounts to $40,000,000. This investment will be used for the development of eldercare facilities and senior living community projects in Canada. Novo is actively working to identify and secure the initial eldercare facility for this project.

Furthermore, Novo disclosed the issuance of an unsecured 15-year $70,000,000 promissory note to RC Consulting LLC in favor of SCP Tourbillion Monaco. The company’s compliance with Nasdaq’s listing requirements has allowed it to regain access to the funds available through the coupon. Underwriting and lender compliance review are currently underway.

Novo Integrated Sciences, Inc. is a healthcare company that aims to revolutionize patient-first health and wellness through a multidisciplinary healthcare ecosystem. By integrating medical technology, advanced therapeutics, and rehabilitative science, Novo offers innovative solutions to deliver healthcare services and products. The company believes that decentralizing healthcare through the integration of technology and interconnectivity is crucial for the future of non-catastrophic healthcare delivery.

For more information about Novo Integrated Sciences, please visit their website at www.novointegrated.com.